Double antibody radioimmunoassay for monitoring metastatic breast cancer.
We previously reported the production of a panel of murine monoclonal antibodies which recognize glycoproteins abnormally expressed in human breast tumours. Using two of these antibodies, a double antibody radioimmunoassay was designed to quantify levels of these breast tumour marker glycoproteins in serum. Marker levels greater than 28 units were considered abnormal. Using this criterion, 63% and 75% of patients with breast cancer stages I and II, respectively, and 88% of those with metastatic disease were found to have elevated marker levels. Thirteen percent of patients with non-malignant breast disease also had elevated marker levels. Elevated marker levels were also detected in patients with non breast neoplasms. One hundred and eleven women with metastatic disease were followed. Eighty-two percent of those with progressive disease and 73% of those where disease regressed had 20% changes in marker levels. These changes in marker levels preceded by up to 6 months changes in disease state. From these results we conclude that this assay may be useful for monitoring the course of disease in breast cancer patients.
Schecter
R L
RL
McGill Cancer Centre, Montreal, Canada.
Major
P P
PP
Kovac
P E
PE
Ishida
M
M
Kovalik
E C
EC
Dion
A S
AS
Langleben
A
A
Boileau
G
G
Boos
G
G
Panasci
L
L
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000097:blood*; D001941:Breast Diseases / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood*; D005260:Female; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D009362:Neoplasm Metastasis / Q000097:blood*; D009363:Neoplasm Proteins / Q000097:blood*; D009369:Neoplasms / Q000097:blood; D011863:Radioimmunoassay / Q000379:methods
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D006023:Glycoproteins; D009363:Neoplasm Proteins